Ricevi le ultime notizie sulle azioni ATAI Life Sciences con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ATAI

Ultime notizie per

ATAI Life Sciences

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

Stuttgart,,Germany,-,05-20-2022:,Person,Holding,Cellphone,With,Logo,Of

Pre-Market Outlook

ATAI

I risultati trimestrali di importanti aziende sono in arrivo, con il potenziale di influenzare l&#39;andamento del mercato.

Wall Street: i report da non perdere e le azioni che movimenteranno la giornata

ATAI Life Sciences NV

Press Releases

ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders

News

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

Financing

atai Life Sciences Announces $50 Million Private Placement Financing

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

Health Care

General

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Earnings

atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

atai Life Sciences to Participate in September Investor Conferences

atai Life Sciences Awarded Grant from the National Institutes of Health

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

CMPS

CYBN

ICAD

LNSR

MNMD

SAGE

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

Avadel Pharmaceuticals plc - Ordinary Share

Avadel Pharmaceuticals

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Cronos Group

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences Hldgs

Harrow

Innoviva

LENZ Therapeutics

Maze Therapeutics

Nektar Therapeutics

Nuvation Bio

Oculis Holding

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Pacira BioSciences

Pharvaris

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Septerna

Trevi Therapeutics

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings

HC Wainwright & Co.

Oppenheimer

Canaccord Genuity

Maxim Group

Screenshot 2024-05-21 at 6.46.56 PM

Biotech

SILO

FTRP

Revolutionizing Mental Healthcare With The Rise Of Ketamine And Psychedelic Therapies

Comments

ATAI Life Sciences Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO